Brief: RAMM Pharma Initiates Clinical Trials Of Its Proprietary Nettavet Cannabinoid Formulation
25/03/2021 11:42
March 25 (Reuters) - Ramm Pharma Corp RAMM.CD :
* RAMM PHARMA INITIATES CLINICAL TRIALS OF ITS PROPRIETARY
NETTAVET™ CANNABINOID FORMULATION FOR MULTIPLE PATHOLOGIES IN
ANIMALS
* RAMM PHARMA CORP - INITIATED CLINICAL TRIALS STUDYING
EFFICACY
OF ITS PROPRIETARY NETTAVET PET CANNABINOID FORMULATION
Source text for Eikon: ID:nGNX8XfhXb
Further company coverage: RAMM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ramm Pharma
See all newsBrief: Ramm Pharma Corp Announces Non-Brokered Private Placement And Intention To Commence Normal Course Issuer Bid
Brief: RAMM Pharma Initiates Clinical Trials Of Its Proprietary Nettavet Cannabinoid Formulation
Brief: Ramm Pharma Enters European Cannabis Market With Strategic Investment In Canapar Corp.